Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
164 studies found for:    Open Studies | "Blood Platelet Disorders"
Show Display Options
Rank Status Study
1 Unknown  Thrombocytopathy in Gaucher Disease Patients
Conditions: Gaucher Disease;   Thrombocytopathy
Intervention:
2 Recruiting Effects of Exercise Training on Cardiovascular Health in Middle-aged Women
Conditions: Menopause;   Cardiac Function Impaired;   Cardiovascular Diseases;   Blood Platelet Disorders;   Metabolic Diseases
Interventions: Behavioral: Yoga/Pilates;   Behavioral: Spinning
3 Recruiting A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Conditions: Primary Myelofibrosis;   Thrombocythemia, Essential;   Thrombocytosis;   Myeloproliferative Disorders;   Bone Marrow Diseases;   Hematologic Diseases;   Blood Coagulation Disorders;   Blood Platelet Disorders;   Hemorrhagic Disorders
Interventions: Drug: LDE225;   Drug: INC424
4 Not yet recruiting Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder
Condition: Inherited Platelet Disorders
Intervention: Other: Blood collection for platelet protein samples
5 Recruiting Safety and Efficacy of Eltrombopag at Escalated Doses
Conditions: Immune Thrombocytopenia;   Platelet Disorder
Interventions: Drug: Eltrombopag;   Drug: Placebo
6 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
7 Recruiting ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
Condition: Immune Thrombocytopenia
Intervention: Drug: Second Line ITP agents
8 Recruiting Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia
Condition: Essential Thrombocythaemia
Interventions: Drug: Anagrelide retard;   Drug: Placebo
9 Not yet recruiting Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Romiplostin
10 Recruiting A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Interventions: Biological: PRM-151;   Drug: Ruxolitinib
11 Unknown  Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
Condition: Purpura, Thrombocytopenic, Idiopathic
Intervention: Drug: rhIL-11
12 Recruiting Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
Conditions: Hemophilia A;   Hemophilia B;   Von Willebrand's Disease
Intervention:
13 Unknown  Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
14 Recruiting Low-dose Decitabine Versus Recombinant Human Thrombopoietin for the Treatment of Refractory Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Decitabine;   Drug: rhTPO
15 Not yet recruiting Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Conditions: Thrombocytopenia;   Alloimmune Platelet Refractoriness
Intervention: Drug: Eculizumab
16 Recruiting Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis;   Post-Polycythemic Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: NS-018
17 Recruiting Eltrombopag for Post Transplant Thrombocytopenia
Condition: Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Placebo
18 Recruiting Sirolimus for Autoimmune Disease of Blood Cells
Conditions: Autoimmune Pancytopenia;   Autoimmune Lymphoproliferative Syndrome (ALPS);   Evans Syndrome;   Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune;   Autoimmune Neutropenia;   Lupus Erythematosus, Systemic;   Inflammatory Bowel Disease;   Rheumatoid Arthritis
Intervention: Drug: sirolimus
19 Recruiting Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Condition: Idiopathic Thrombocytopenic Purpura
Intervention:
20 Unknown  Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Interventions: Drug: Antox tablets(Mepaco);   Other: drug therapy for ITP

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years